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porting this theory. First, the patient received the transplant 
16 years before the development of renal failure. Graft sur- 
vival after the first year declines logarithmically out to at least 
10 years, and probably longer. Therefore, the chance of 
chronic rejection occurring at 16 years is fairly high (i.e., ap- 
proximately 36%).* Second, his patient had a serum creati- 
nine value of 2.0 mg/dl 5 years after completion of cisplatin 
therapy; this value rose in the sixth year after treatment. Cis- 
platin nephrotoxicity most often becomes evident during ther- 
apy or within 6 months after therapy and then stabilizes once 
therapy is d i s~ont inued .~ ,~  Therefore, although cisplatin neph- 
rotoxicity cannot be entirely ruled out in this case, it does not 
represent a classic presentation. 
We do not believe that the study by Bajorin et aL5 pre- 
cludes the use of carboplatin in these patients because no 
significant difference in survival or remission duration was 
demonstrated. Their study compared a regimen of carbopla- 
tin plus etoposide with a regimen of cisplatin plus etoposide 
in patients with metastatic germ cell tumors. Recently, Hor- 
wich e t  a l .  concluded that a combination of carboplatin, eto- 
poside, and bleomycin was an effective and less toxic alterna- 
tive to cisplatin-based chemotherapy in patients with meta- 
static nonseminomatous germ cell tumors with a good 
prognosis.6 We believe that carboplatin may yet prove to be a 
valid treatment option for renal transplant recipients who re- 
quire platinum-containing compounds. 
We strongly agree that measures for prevention of neph- 
rotoxicity, including hydration and mannitol, must be taken 
in all patients receiving cisplatin. We also agree that all renal 
transplant patients who require therapy with cisplatin should 
be described in the literature because this is a subject of grow- 
ing concern. 
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The Dutch multicenter group recently published a first analy- 
sis of a prospective, randomized trial. The aim of the trial was 
to assess the impact of adjuvant postoperative radiation ther- 
apy in rectal cancer Stage BII, CI, and CII. Patient accrual was 
stopped as soon as 172 patients had entered the study. 
Eighty-eight patients were entered in the treatment arm. 
Eighty-four patients were entered in the control arm. There 
was a slight imbalance favoring the control arm concerning 
prognostic factors such as histologic differentiation (poorly 
differentiated tumors, 17% in the treatment arm versus 6% in 
the control arm) and tumor location (more lower tumors in 
the treatment arm). 
Sixty-four of the 88 patients designated at random to the 
radiation therapy arm received the adequate dose according 
to protocol prescription (50 Gy in 5 weeks). In ten cases there 
was a dose reduction. Moreover, 14 patients did not receive 
radiation therapy at all (Table 1). 
The local control seems to be better in the treated group. 
However, this difference does not reach a statistically signifi- 
cant level. The authors were looking for a 50% difference. 
The alpha and beta risks are not mentioned in the current 
publication. 
We analyzed the difference in crude local recurrence as a 
function of whether the patients received the prescribed dose 
in the radiation therapy arm (chi-square, 4.61; P < 0.05). To- 
gether with the imbalance in prognostic factors, these proto- 
col violations could be at the origin of the lack of significant 
impact on local control. Assuming that treatment according to 
protocol results in the correct figures concerning recurrence 
rate, the total expected incidence of local recurrence should be 
10/88. Moreover, the exclusion of 16 patients (14 who did 
not receive radiation therapy according to protocol and 2 who 
received radiation therapy although they were not members 
of the control arm) results in a marginal significant reduction 
of the actuarial local relapse rate. 
The increased number of poorly differentiated and lower 
tumors in the radiation therapy group results in an increased 
incidence of distant metastatic disease (26% versus 39%). This 
imbalance in prognostic factors and the high number of local 
recurrences in those patients designated to receive 50 Gy who 
did not (14 of 24) disfavors the radiation therapy arm having 
a higher actuarial relapse-free survival rate than the surgery 
alone arm. 
We do not understand why this trial has been closed, 
knowing the high incidence of protocol violations. The argu- 
ment that it is difficult to understand why refusal of therapy 
would imply a higher chance of recurrence does not hold 
looking at the imbalance in prognostic factors between the 
treatment arms. 
The assessment that rectal cancer could be radioresistant 
if only 50 Gy was applied is not based on hard data. There are 
no large series of in uivo measurement of intrinsic radioresis- 
tance. According to Malaise and Fertil, the alpha value for 
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colorectal cancer is an intermediate value considering differ- 
ent established cell lines of human origin.' Moreover, biologic 
efficacy of a treatment depends not only on intrinsic radiore- 
sistance, but also on reoxygenation, redistribution, repair, and 
repopulation. Concerning repopulation, recently published 
data yield low values for potential doubling time in colorectal 
cancer, especially for poorly differentiated tumors. This could 
indicate the need for accelerating treatment in subgroups of 
patients with extremely rapidly proliferating tumors, rather 
than increasing total dose. 
These data cannot be considered evidence of lack of im- 
pact on local control or survival of adjuvant postoperative 
radiation therapy in rectal cancer. 
Table 1. 
No. Recurrence 
Treatment according to protocol 64 (73%) 7 (11%) 
Treatment not according to protocol 24 (27%) 14 (58%) 
Tota l  88 (100%) 21 "24%) 
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Reply to  Coucke 
We object to the figures produced by Dr. Coucke regarding 64 
patients. We did not provide recurrence rates for ten patients 
who received a lower dose of radiation. 
In a randomized trial, one considers a large number of 
factors of imbalance and one might expect 1/20 factors to 
h a v e  a statistically significant difference ( P  < 0.05). I n  this 
study, the imbalance between arms with respect to grade of 
differentiation and location was not statistically significant. 
Moreover, multivariate Cox regression analysis showed 
only moderate associations between grade of differentiation 
or site of disease and failure rate, and this association was far 
from being statistically significant. The major and statistically 
significant factor is Dukes' Astler Coller stage; with respect to 
this factor, the treatment arms are balanced. We object to the 
suggestion that an imbalance of prognostic factors would ex- 
plain the lower relapse-free survival rate in the radiation ther- 
apy arm. 
Regarding the closing of the trial, there is a decrease in 
accrual in any trial after a number of years. One can hope that 
the combination of results in meta analysis will strengthen 
conclusions. 
The interpretation of the radioresistance is difficult. How- 
ever, the success of a lower preoperative dose suggests a role 
of oxygenation. 
A. D. Treurniet-Donker, MD 
W. L. J .  van Putten, MSc 
Departments of Radiotherapy 
Dr. Daniel de Hoed Cancer Center 
Rotterdam, The Netherlands 
and Statistics 
Treurniet-Donker ct a/.' reported the results of an interim 
analysis of a prospective trial on postoperative radiation ther- 
apy for rectal adenocarcinoma. They concluded that postoper- 
ative radiation therapy alone cannot be justified as a routine 
procedure in the primary management of resectable rectal 
cancer. In our opinion, this conclusion is highly preliminary 
and unsupported by their data for several reasons. 
First, the relatively small number of patients suggests 
that at least some preselection by the participating centers 
could have taken place before randomization. 
Second, the radiation therapy arm consisted of only 88 
patients, of which 14 (16%) did not receive irradiation for 
various reasons. Another ten patients (1 1 %) received a total 
dose of 4000 cCy or less. In the control group, two patients 
received radiation therapy. Notwithstanding the fact that 
only 73% of the patients in the radiation therapy group re- 
ceived treatment as prescribed, the so-called "intention-to- 
treat principle" was applied in the statistical analysis of the 
results in the two arms of the trial. Doing so introduced an 
important bias. It is well known that more than 20% protocol- 
violations make any comparison in any trial unreliable. We 
think these patients should have been excluded from the anal- 
Third, the 16 patients who did not receive treatment ac- 
cording to randomization did rather badly, with only 3 alive 
and disease-free at  the time of analysis. A separate analysis 
excluding these patients showed a statistically significant 
lower local relapse rate in the radiation therapy group. The 
ten patients who received a suboptimal dose of 4000 cCy or 
less were included in this separate analysis. However, no spe- 
cific information concerning those ten patients was provided 
by the authors. 
Fourth, in the calculation of disease-free survival, death 
was regarded as an event or a failure, even if the patients died 
intercurrently without evidence of disease (7  of 37 in the radia- 
tion therapy group and 5 of 29 in the control group). No dis- 
ease-specific survival results were mentioned. The incidence 
ysis. 
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of metastasis was higher in the radiation therapy arm (39% 
zwsus 26%), resulting in a higher death rate. This difference 
was, for this relatively small population, attributed to chance 
fluctuation. It might, as stated by the authors, indeed mask 
any influence of improved local control on survival. We think 
that the influence on disease-specific survival rates would be 
even more important. The same conclusions can be drawn 
concerning the higher incidence of poorly differentiated ade- 
nocarcinoma in the radiation therapy arm (1 7% uersus 6%). 
Further proof of the imbalance in patient distribution is the 
predominance of the abdominoperineal resection in the irra- 
diated group (56% versus 46%). 
Finally, Table 2, which summarizes relapse and survival 
numbers, contains, in our opinion, three mistakes in the col- 
umn "Received RT." After reconstructing the table using the 
numbers of events mentioned in Table 2 and in the text, the 
differences between the two groups in terms of sites of recur- 
rence (local versus distant) are highlighted. 
The two groups are not truly comparable because of the 
limited number of patients, the differences in patient charac- 
teristics, and the large number of patients who did not receive 
treatment according to randomization. However, a definite 
trend (according to the analysis of the authors this trend was 
statistically significant!) toward a reduction of the local re- 
lapse rate in the irradiated group (excluding the patients who 
were not irradiated, but including ten patients who received a 
suboptimal dose of radiation remains). 
Local recurrence constitutes a major threat to the quality 
of life of our patients. This study has strengthened our opin- 
ion that every patient who received radical surgery for rectal 
cancer, Stages B2 and C or International Union Against 
Cancer Stages 111 and IV, should be offered a full course of 
postoperative radiation therapy to reduce the probability of a 
local relapse. 
Recent  publication^^-^ suggest the addition of chemother- 
apy to postoperative radiation therapy, using the cytotoxic 
drugs as radiosensitizers and/or as adjuvant therapy. This 
causes a remarkable shift in the discussion on postoperative 
radiation therapy from the former "to irradiate or not to irra- 
diate?" to the current "to irradiate in combination with 
what?" question. 
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Rep2y to Poortmans 
When this trial was started it was the intention of most of us 
not only to prove the value of postoperative radiation therapy 
in rectal cancer, but also to quantify this value to be able to 
make it a standard therapy. Other investigators (Gastrointesti- 
nal Tumor Study Group,' National Surgical Adjuvant Breast 
Project,2 Balslev3 [Denmark], Medical Research Council 
[MRC],4 and European Organization for Research and Treat- 
ment of Cancer [EORTC]) started similar studies in the past 
decade. All except EORTC have published their results so far 
and they reinforce our conclusions. 
As for point 1 in the criticism by Poortmans and Hamers, 
172 is not a large number of patients and is identical to the 
EORTC a~hievement.~ Preselection cannot be proven or com- 
pletely avoided in any large multicenter project, but random- 
ization eliminates the weight of this point. In this study there 
is no reason to assume that the selection process may affect 
the ability to generalize the results. 
Point 2 is the most important issue raised because it con- 
cerns the basis of randomization, which is the production of 
comparable groups of patients to test the effect of a certain 
treatment. Application of the intention-to-treat principle does 
not introduce an important bias; on the contrary, this princi- 
ple is the only way to prevent a bias. Refusal is regrettable, 
but can happen in any treatment offer. In the National Surgi- 
cal Adjuvant Breast Project study of Fisher et there were 
22  refusals among 184 patients in the treatment arm. They 
should not be (and were not) excluded from the analysis. Pa- 
tients who could not fulfill the complete course of treatment 
can i iczw be excluded because they would not have been able 
to complete the treatment even if it were standard therapy. 
Exclusion would have created a serious b i a ~ . ~ , ~  
Regarding points 3 and 5, we did our analysis after ex- 
cluding 16 patients who did not receive treatment according 
to the arm of randomization. Table 2 shows detailed data 
beyond the randomization on request of one of the reviewers 
of C a ~ c e t - .  Thus, one can analyze separately as Poortmans and 
€lamers have done after excluding patients not treated ac- 
cording to protocol. However, this expresses unwillingness to 
accept the rules regarding randomized trials and statistical 
interpretation when the outcome does not reinforce long held 
beliefs in some standard practice. 
Concerning point 4, it is becoming standard practice to 
separate the cancer-related death rate from the total death 
rate figure. However, this should be viewed with caution be- 
cause data regarding actual cause of death tend to be unreli- 
able. Furthermore, there is treatment-related death that 
should not be hidden. We covered disease-specific end points 
sufficiently by the analysis of local relapse and distant re- 
lapse-free survival data. The slight difference between the 
groups of patients regarding histologic type and type of sur- 
gery is not of major importance. 
A definite trend toward a reduction of the local relapse 
rate is not enough of an argument for standardizing a treat- 
ment that has toxic effects (two deaths!) and implies, at least 
in 85% of patients, overtreatment at high cost. Recently, some 
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data' came forth suggesting that preoperative radiation ther- 
apy may be more effective than postoperative radiation 
therapy. 
The value of radiation therapy in primary treatment of 
rectal cancer has not been sufficiently investigated to make 
final recommendations on standard treatment. 
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